A plan to slash Food and Drug Administration drug review times is raising alarms at the public health agency that's been ...

Dr. Martin Makary testifies during his confirmation hearing before the Senate Committee on Health, Education, Labor, and Pensions Committee on March 06, 2025, in Washington, DC. This story was ...

WASHINGTON (AP) — U.S. regulators will begin offering faster reviews to new medicines that administration officials deem as promoting “the health interests of Americans,” under a new initiative ...

Jan 15 (Reuters) - The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for the Trump administration ...

Food and Drug Administration commissioner Marty Makary's flagship effort to overhaul how the agency reviews drugs is facing intensifying scrutiny from Congress and the medical establishment over ...

FDA delays drug reviews for two priority voucher drugs amid safety and efficacy concerns, extending timelines for Sanofi and Disc Medicine products.

Geriatrics and Aging. 2005;8(6):43-45. Is the treatment still indicated or has the diagnosis been refuted? For example, a putative diagnosis of angina may have subsequently been disproved. Treatments ...

A study found that clinical pharmacist-led reviews of hospital medications for older adults with hip fractures were linked to significantly lower rates of adverse drug reactions (ADRs). The research, ...

Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.

WASHINGTON (AP) — U.S. regulators will begin offering faster reviews to new medicines that administration officials deem as promoting “the health interests of Americans,” under a new initiative ...